FDA Approves Penpulimab-kcqx for Non-keratinizing Nasopharyngeal Carcinoma By Ogkologos - May 23, 2025 625 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study AK105-304 and Study AK105-202 Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR InflaMix Identifies CAR-T Recipients with a Preinfusion Inflammatory Profile Indicative of... May 5, 2025 FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed... January 22, 2021 EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /... June 28, 2024 FDA Approves Sirolimus Protein-Bound Particles for Malignant Perivascular Epithelioid Cell Tumour November 26, 2021 Load more HOT NEWS Qué deben saber los latinos sobre dejar de fumar y las... Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer Professor Eithne Costello: On the road to early detection Topotecan–Berzosertib Combination Shows Promise against Small Cell Lung Cancer
